Russian Journal of Child NeurologyRussian Journal of Child NeurologyРусский журнал детской неврологии2073-88032412-9178Publishing House ABV Press49410.17650/2073-8803-2024-19-4-29-41REVIEWS AND LECTURESОБЗОРЫ И ЛЕКЦИИSelective serotonin reuptake inhibitors in pediatric neurology: a safety issue (systematic review)Селективные ингибиторы обратного захвата серотонина в детской неврологии: проблема безопасности (систематический обзор)https://orcid.org/0000-0002-2840-837XShnayderN. A.ШнайдерН. А.
Russian Federation

Natalya Alekseevna Shnayder

3 Bekhtereva St., Saint Petersburg 192019

1 Partizana Zheleznyaka St., Krasnoyarsk 660022

Наталья Алексеевна Шнайдер 

192019 Санкт-Петербург, ул. Бехтерева, 3

660022 Красноярск, ул. Партизана Железняка, 1

naschnaider@yandex.ruhttps://orcid.org/0009-0004-1752-094XMakarovE. A.МакаровЕ. А.
Russian Federation

3 Bekhtereva St., Saint Petersburg 192019

192019 Санкт-Петербург, ул. Бехтерева, 3

https://orcid.org/0009-0006-8999-9296KidyaevaA. V.КидяеваА. В.
Russian Federation

3 Bekhtereva St., Saint Petersburg 192019

126 Naberezhnaya reki Moyki, Saint Petersburg 190121

192019 Санкт-Петербург, ул. Бехтерева, 3

190121 Санкт-Петербург, Набережная реки Мойки, 126

https://orcid.org/0000-0001-8279-4198GrechkinaV. V.ГречкинаВ. В.
Russian Federation

3 Bekhtereva St., Saint Petersburg 192019

192019 Санкт-Петербург, ул. Бехтерева, 3

https://orcid.org/0000-0002-8493-0058PetrovaM. M.ПетроваМ. М.
Russian Federation

1 Partizana Zheleznyaka St., Krasnoyarsk 660022

660022 Красноярск, ул. Партизана Железняка, 1

https://orcid.org/0000-0003-1874-9434NasyrovaR. F.НасыроваР. Ф.
Russian Federation

3 Bekhtereva St., Saint Petersburg 192019

9 Prospekt Lenina, Tula 300012

192019 Санкт-Петербург, ул. Бехтерева, 3

300012 Тула, проспект Ленина, 92

V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии им. В.М. Бехтерева» Минздрава РоссииKrasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky, Ministry of Health of RussiaФГБОУ ВО «Красноярский государственный медицинский университет им. проф. В.Ф. Войно-Ясенецкого» Минздрава РоссииState Psychiatric Hospital of St. Nicholas the wonderworkerСПб ГКУЗ «Психиатрическая больница Святого Николая Чудотворца»Tula State University, Ministry of Education and Science of RussiaФГБОУ ВО «Тульский государственный университет» Минобрнауки России1512202419429412201202522012025Copyright ©; 2024, ABV-PressCopyright ©; 2024, АБВ-пресс2024ABV-PressАБВ-прессhttps://rjdn.abvpress.ru/jour/about/editorialPolicieshttps://rjdn.abvpress.ru/jour/article/view/494

The authors searched, analyzed and systematized the results of domestic and foreign studies of selective serotonin reuptake inhibitors-induced QT prolongation and the risk of Torsade de pointes (full-text versions of original articles, clinical cases, systemic reviews, meta-analyses, Cochrane reviews) in Russian and English languages available in bibliographic databases (eLIbRARY, PubMed, Scopus, Springer, ClinicalKeys, Oxford Press, Google Scholar, MedCredit, Drugbank, PharmGKb) to update the knowledge of practicing neurologists, cardiologists, clinical pharmacologists and general practitioners (physicians, pediatricians) about the possibility of predicting and preventing life-threatening cardiac adverse reactions. From the obtained results it can be judged that escitalopram and citalopram have a potentially high risk. Despite of the fact that sertraline is approved to use in children and adolescents both in the Russian Federation as well as abroad, studies show it significantly affects the QT interval at therapeutic and toxic doses. The safety was demonstrated by fluvoxamine and fluoxetine. Studies of these selective serotonin reuptake inhibitors didn’t show a statistically significant increase of the QT interval.

Авторы провели поиск, анализ и систематизацию результатов отечественных и зарубежных исследований индуцированного селективными ингибиторами обратного захвата серотонина удлинения интервала QT и риска развития пароксизмальной пируэтной желудочковой тахикардии Torsade de pointes (полнотекстовые версии оригинальных статей, клинических случаев, системных обзоров, метаанализов, кокрейновские обзоры) на русском и английском языках, доступных в наукоемких библиографических базах данных (eLIbRARY, PubMed, Scopus, Springer, ClinicalKeys, Oxford Press, Google Scholar, MedCredit, Drugbank, PharmGKb), для обновления знаний практикующих неврологов, кардиологов, клинических фармакологов и врачей общей практики (терапевтов, педиатров) о возможности прогнозирования и профилактики жизнеугрожающих кардиологических нежелательных реакций. Наиболее высокий риск показан для эсциталопрама и циталопрама. Несмотря на то что сертралин разрешен к применению у детей как в Российской Федерации, так за рубежом, исследования свидетельствуют о его значимом влиянии на интервал QT в терапевтических и токсических дозах. Наибольшую безопасность продемонстрировали флувоксамин и флуоксетин; исследования этих препаратов не показали статистически значимого увеличения интервала QT.

selective serotonin reuptake inhibitorsadverse drug reactioncardiotoxicitylong QT interval syndrometorsade de pointesventricular tachycardiasudden cardiac deathселективные ингибиторы обратного захвата серотонинанежелательные лекарственные реакциикардиотоксичностьсиндром удлиненного интервала QTпируэтная тахикардияжелудочковая тахикардиясиндром внезапной смертиState Register of Drugs. Available at: https://grls.rosminzdrav.ru/Default.aspx. (In Russ.).Государственный реестр лекарственных средств. Доступно по: https://grls.rosminzdrav.ru/Default.aspx.Danilov D.S. Antidepressants are selective serotonin neuronal reuptake inhibitors: 40-year history. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics 2015;1(7):66–74. (In Russ.). DOI: 10.14412/2074-2711-2015-1-66-74Данилов Д.С. Антидепрессанты – селективные ингибиторы обратного нейронального захвата серотонина: 40-летняя история. Неврология, нейропсихиатрия, психосоматика 2015;19(1):18–24. DOI: 10.14412/2074-2711-2015-1-66-74Clinical Psychopharmacogenetics. Ed. by R.F. Nasyrova, N.G. Neznanov. Saint-Petersburg: DEAN, 2020. 408 p. (In Russ).Клиническая психофармакогенетика. Под ред. Р.Ф. Насыровой, Н.Г. Незнанова. СПб.: ДЕАН, 2020. 408 с.Malin D.I., Ryvkin P.V., Bulatova D.R. QT prolongation syndrome with antipsychotic and antidepressant drugs. Sovremennaya terapiya psikhicheskikh rasstroystv = Current Therapy of Mental Disorders 2023;(2):48–56. (In Russ.). DOI: 10.21265/PSYPH.2023.69.57.006Малин Д.И., Рывкин П.В., Булатова Д.Р. Синдром удлиненного интервала QT при применении антипсихотических и антидепрессивных препаратов. Современная терапия психических расстройств 2023;(2):48–56. DOI: 10.21265/PSYPH.2023.69.57.006Nesterets A.M., Maksimov V.N. Molecular genetic markers of QT interval duration and sudden cardiac death: literature review. Byulleten sibirskoy meditsiny = Bulletin of Siberian Medicine 2022;21(1):133–43. (In Russ.). DOI: 10.20538/1682-0363-2022-1-133-143Нестерец А.М., Максимов В.Н. Молекулярно-генетические маркеры длительности интервала QT и внезапная сердечная смерть: обзор литературы. Бюллетень сибирской медицины 2022;21(1):133–43. DOI: 10.20538/1682-0363-2022-1-133-143Ostroumova O.D., Goloborodova I.V. Drug-induced long QT interval: prevalence, risk factors, treatment and prevention. Consilium Medicum 2019;21(3):62–7. (In Russ.). DOI: 10.26442/20751753.2019.5.190415Остроумова О.Д., Голобородова И.В. Лекарственно-индуцированное удлинение интервала QT: распространенность, факторы риска, лечение и профилактика. Consilium Medicum 2019;21(5):62–7.Shnayder N.A., Khasanova A.K., Nasyrova R.F. First phase of antipsychotic metabolism in the liver: the role of oxidation. Farmakogenetika i farmakogenomika = Pharmacogenetics and Pharmacogenomics 2022;(1):15–30. (In Russ). DOI: 10.37489/2588-0527-2022-1-15-30Шнайдер Н.А., Хасанова А.К., Насырова Р.Ф. Первая фаза метаболизма антипсихотиков в печени: роль окисления. Фармакогенетика и фармакогеномика 2022;(1):15–30. DOI: 10.37489/2588-0527-2022-1-15-30Abbas R., Riley S., LaBadie R.R. et al. A thorough qt study to evaluate the effects of a supratherapeutic dose of sertraline on cardiac repolarization in healthy subjects. Clin Pharmacol Drug Dev 2020;9(3):307–20. DOI: 10.1002/cpdd.749Abbas R., Riley S., LaBadie R.R. et al. A thorough qt study to evaluate the effects of a supratherapeutic dose of sertraline on cardiac repolarization in healthy subjects. Clin Pharmacol Drug Dev 2020;9(3):307–20. DOI: 10.1002/cpdd.749Aronow W.S., Shamliyan T.A. Effects of antidepressants on QT interval in people with mental disorders. Arch Med Sci. 2020;16(4):727–41. DOI: 10.5114/aoms.2019.86928Aronow W.S., Shamliyan T.A. Effects of antidepressants on QT interval in people with mental disorders. Arch Med Sci. 2020;16(4):727–41. DOI: 10.5114/aoms.2019.86928Banerjee S., Butcher R. Pharmacological interventions for chronic pain in pediatric patients: A review of Guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2020.Baumel W.T., Mills J.A., Schroeder H.K. et al. Gastrointestinal symptoms in pediatric patients with anxiety disorders and their relationship to selective serotonin reuptake inhibitor treatment or placebo. Child Psychiatry Hum Dev 2023. DOI: 10.1007/s10578-023-01586-xBaumel W.T., Mills J.A., Schroeder H.K. et al. Gastrointestinal symptoms in pediatric patients with anxiety disorders and their relationship to selective serotonin reuptake inhibitor treatment or placebo. Child Psychiatry Hum Dev 2023. DOI: 10.1007/s10578-023-01586-xCooper T.E., Heathcote L.C., Clinch J. et al. Antidepressants for chronic non-cancer pain in children and adolescents. Cochrane Database Syst Rev 2017;8(8):CD012535. DOI: 10.1002/14651858.CD012535.pub2Cooper T.E., Heathcote L.C., Clinch J. et al. Antidepressants for chronic non-cancer pain in children and adolescents. Cochrane Database Syst Rev 2017;8(8):CD012535. DOI: 10.1002/14651858.CD012535.pub2Cubeddu L.X. Drug-induced inhibition and trafficking disruption of ion channels: Pathogenesis of QT abnormalities and druginduced fatal arrhythmias. Curr Cardiol Rev 2016;12(2):141–54. DOI: 10.2174/1573403x12666160301120217Cubeddu L.X. Drug-induced inhibition and trafficking disruption of ion channels: Pathogenesis of QT abnormalities and druginduced fatal arrhythmias. Curr Cardiol Rev 2016;12(2):141–54. DOI: 10.2174/1573403x12666160301120217Cubeddu L.X. Iatrogenic QT abnormalities and fatal arrhythmias: Mechanisms and clinical significance. Curr Cardiol Rev 2009;5(3):166–76. DOI: 10.2174/157340309788970397Drye L.T., Spragg D., Devanand D.P. et al. Changes in QTc interval in the citalopram for agitation in Alzheimer’s disease (CitAD) randomized trial. PLoS One 2014;9(6):e98426. DOI: 10.1371/journal.pone.0098426Drye L.T., Spragg D., Devanand D.P. et al. Changes in QTc interval in the citalopram for agitation in Alzheimer’s disease (CitAD) randomized trial. PLoS One 2014;9(6):e98426. DOI: 10.1371/journal.pone.0098426Edinoff A.N., Akuly H.A., Hanna T.A. et al. Selective serotonin reuptake inhibitors and adverse effects: A narrative review. Neurol Int 2021;13(3):387–401. DOI: 10.3390/neurolint13030038Elsayed M., Abdel-Kahaar E., Gahr M. et al. Arrhythmias related to antipsychotics and antidepressants: An analysis of the summaries of product characteristics of original products approved in Germany. Eur J Clin Pharmacol 2021;77(5):767–75. DOI: 10.1007/s00228-020-03049-xElsayed M., Abdel-Kahaar E., Gahr M. et al. Arrhythmias related to antipsychotics and antidepressants: An analysis of the summaries of product characteristics of original products approved in Germany. Eur J Clin Pharmacol 2021;77(5):767–75. DOI: 10.1007/s00228-020-03049-xFDA: Drug Approvals and Databases. Available at: https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases.FDA: Drug Approvals and Databases. Available at: https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases.Funk K.A., Bostwick J.R. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother 2013;47(10):1330–41. DOI: 10.1177/1060028013501994Funk K.A., Bostwick J.R. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother 2013;47(10):1330–41. DOI: 10.1177/1060028013501994Gupta N., Gupta M. Off-label psychopharmacological interventions for autism spectrum disorders: Strategic pathways for clinicians. CNS Spectr 2024;29(1):10–25. DOI: 10.1017/S1092852923002389Iribarren C., Round A.D., Peng J.A. et al. Validation of a populationbased method to assess drug-induced alterations in the QT interval: A self-controlled crossover study. Pharmacoepidemiol Drug Saf 2013;22(11):1222–32. DOI: 10.1002/pds.3479Iribarren C., Round A.D., Peng J.A. et al. Validation of a populationbased method to assess drug-induced alterations in the QT interval: A self-controlled crossover study. Pharmacoepidemiol Drug Saf 2013;22(11):1222–32. DOI: 10.1002/pds.3479Maljuric N.M., Noordam R., Aarts N. et al. Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: The population-based Rotterdam Study. Br J Clin Pharmacol 2015;80(4):698–705. DOI: 10.1111/bcp.12681Maljuric N.M., Noordam R., Aarts N. et al. Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: The population-based Rotterdam Study. Br J Clin Pharmacol 2015;80(4):698–705. DOI: 10.1111/bcp.12681Nosè M., Barbui C. Do antidepressants prolong the QT interval? Epidemiol Psychiatr Sci 2014;23(1):19–20. DOI: 10.1017/S204579601300070XNosè M., Barbui C. Do antidepressants prolong the QT interval? Epidemiol Psychiatr Sci 2014;23(1):19–20. DOI: 10.1017/S204579601300070XOjero-Senard A., Benevent J., Bondon-Guitton E. et al. A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology (Berl) 2017;234(20):3075–81. DOI: 10.1007/s00213-017-4685-7Ojero-Senard A., Benevent J., Bondon-Guitton E. et al. A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology (Berl) 2017;234(20):3075–81. DOI: 10.1007/s00213-017-4685-7Okayasu H., Ozeki Y., Fujii K. et al. Investigation of the proarrhythmic effects of antidepressants according to QT Interval, QT dispersion and T wave peak-to-end interval in the clinical setting. Psychiatry Investig 2019;16(2):159–66. DOI: 10.30773/pi.2018.12.11Okayasu H., Ozeki Y., Fujii K. et al. Investigation of the proarrhythmic effects of antidepressants according to QT Interval, QT dispersion and T wave peak-to-end interval in the clinical setting. Psychiatry Investig 2019;16(2):159–66. DOI: 10.30773/pi.2018.12.11OMIM: Online Mendelian Inheritance in Man. An Online Catalog of Human Genes and Genetic Disorders. Available at: https://www.omim.org/.OMIM: Online Mendelian Inheritance in Man. An Online Catalog of Human Genes and Genetic Disorders. Available at: https://www.omim.org/.Otsuka Y. Paroxetine-induced QTc prolongation. J Gen Fam Med 2017;18(6):442–5. DOI: 10.1002/jgf2.137PRISMA: Transparent Reporting of Systematic Reviews and Meta-Analyses. Available at: http://www.prisma-statement.org/PRISMAStatement/.PRISMA: Transparent Reporting of Systematic Reviews and Meta-Analyses. Available at: http://www.prisma-statement.org/PRISMAStatement/.Roohafza H., Pourmoghaddas Z., Saneian H., Gholamrezaei A. Citalopram for pediatric functional abdominal pain: A randomized, placebo-controlled trial. Neurogastroenterol Motil 2014;26(11):1642–50. DOI: 10.1111/nmo.12444Roohafza H., Pourmoghaddas Z., Saneian H., Gholamrezaei A. Citalopram for pediatric functional abdominal pain: A randomized, placebo-controlled trial. Neurogastroenterol Motil 2014;26(11):1642–50. DOI: 10.1111/nmo.12444Ryan K., Benz P., Zosel A. et al. QTc Prolongation in poison center exposures to CredibleMeds list of substances with “Known Risk of Torsades de Pointes”. Cardiovasc Toxicol 2022;22(9):866–77. DOI: 10.1007/s12012-022-09764-4Ryan K., Benz P., Zosel A. et al. QTc Prolongation in poison center exposures to CredibleMeds list of substances with “Known Risk of Torsades de Pointes”. Cardiovasc Toxicol 2022;22(9):866–77. DOI: 10.1007/s12012-022-09764-4Schwartz P.J., Ackerman M.J., George A.L.Jr., Wilde A.A.M. Impact of genetics on the clinical management of channelopathies. J Am Coll Cardiol 2013;62(3):169–80. DOI: 10.1016/j.jacc.2013.04.044.Schwartz P.J., Ackerman M.J., George A.L.Jr., Wilde A.A.M. Impact of genetics on the clinical management of channelopathies. J Am Coll Cardiol 2013;62(3):169–80. DOI: 10.1016/j.jacc.2013.04.044.Sharan L. Campleman, Brent J., Pizon A.F. et al. Drug-specific risk of severe QT prolongation following acute drug overdose. Clin Toxicol (Phila) 2020;58(12):1326–34. DOI: 10.1080/15563650.2020.1746330Shnayder N.A., Kidyaeva A.V., Vaiman E.E. et al. Role of pharmacokinetics and pharmacogenetics of antidepressantinduced prolongation of the QT interval and Torsade de Pointes in patients with mental disorders. Personalized Psychiatry and Neurology 2023;3(2):72–119. DOI: 10.52667/2712-9179-2023-3-2-72-119Shnayder N.A., Kidyaeva A.V., Vaiman E.E. et al. Role of pharmacokinetics and pharmacogenetics of antidepressantinduced prolongation of the QT interval and Torsade de Pointes in patients with mental disorders. Personalized Psychiatry and Neurology 2023;3(2):72–119. DOI: 10.52667/2712-9179-2023-3-2-72-119Simon L.V., Keenaghan M. Serotonin Syndrome. In: StatPearls. Treasure Island: StatPearls Publishing, 2023.Straley C.M., Sochacki M., Reed E. et al. Comparison of the effect of citalopram, bupropion, sertraline, and tricyclic antidepressants on QTc: A cross-sectional study. J Affect Disord 2022;296:476–84. DOI: 10.1016/j.jad.2021.08.149Strawn J.R., Mills J.A., Poweleit E.A. et al. Adverse effects of antidepressant medications and their management in children and adolescents. Pharmacotherapy 2023;43(7):675–90. DOI: 10.1002/phar.2767Strawn J.R., Mills J.A., Poweleit E.A. et al. Adverse effects of antidepressant medications and their management in children and adolescents. Pharmacotherapy 2023;43(7):675–90. DOI: 10.1002/phar.2767Turnheim K. Unerwünschte Wirkung von Psychopharmaka im Alter [Adverse effects of psychotropic drugs in the elderly]. Wien Klin Wochenschr 2000;112(9):394–401.Turnheim K. Unerwünschte Wirkung von Psychopharmaka im Alter [Adverse effects of psychotropic drugs in the elderly]. Wien Klin Wochenschr 2000;112(9):394–401.Vaiman E.E., Shnayder N.A., Zhuravlev N.M. et al. Genetic biomarkers of antipsychotic-induced prolongation of the QT interval in patients with schizophrenia. Int J Mol Sci 2022;23:15786. DOI: 10.3390/ijms232415786Van Haelst I.M., van Klei W.A., Doodeman H.J. et al. QT interval prolongation in users of selective serotonin reuptake inhibitors in an elderly surgical population: A cross-sectional study. J Clin Psychiatry 2014;75(1):15–21. DOI: 10.4088/JCP.13m08397 Wallace E., Howard L., Liu M. et al. Long QT syndrome: Genetics and future perspective. Pediatr Cardiol 2019;40(7):1419–30. DOI: 10.1007/s00246-019-02151-xVan Haelst I.M., van Klei W.A., Doodeman H.J. et al. QT interval prolongation in users of selective serotonin reuptake inhibitors in an elderly surgical population: A cross-sectional study. J Clin Psychiatry 2014;75(1):15–21. DOI: 10.4088/JCP.13m08397 Wallace E., Howard L., Liu M. et al. Long QT syndrome: Genetics and future perspective. Pediatr Cardiol 2019;40(7):1419–30. DOI: 10.1007/s00246-019-02151-xWang G.K., Mitchell J., Wang S.Y. Block of persistent late Na+ currents by antidepressant sertraline and paroxetine. J Membr Biol 2008;222(2):79–90. DOI: 10.1007/s00232-008-9103-yWilde A.A., Roden D.M. Predicting the long-QT genotype from clinical data: From sense to science. Circulation 2000;102(23):2796–8. DOI: 10.1161/01.cir.102.23.2796Yamazaki-Hashimoto Y., Nakamura Y., Ohara H. et al. Fluvoxamine by itself has potential to directly induce long QT syndrome at supra-therapeutic concentrations. J Toxicol Sci 2015;40(1):33–42. DOI: 10.2131/jts.40.33